SEC Form 4 · accession 0001654954-18-007089
PALATIN TECHNOLOGIES INC · PTN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carl Spana
Officer — President and CEO · Director
Period of report
Jun 26, 2018
Accepted (ET)
Jun 28, 2018 · 4:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000911216
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 26, 2018 | A | 187,500 | $0.00 | A | 3,774,352 | D | |
| Common StockF2 | Jun 26, 2018 | A | 356,000 | $0.00 | A | 4,130,352 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $1.00 | Jun 26, 2018 | A | 533,000 | A | Jun 26, 2019 | Jun 26, 2028 | Common Stock | 533,000 | 533,000 | D |
| Stock Option (right to buy)F4 | $0.85 | Jun 26, 2018 | A | 187,500 | A | Jun 26, 2018 | Dec 12, 2027 | Common Stock | 187,500 | 187,500 | D |
Explanation of responses
- F1Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made December 12, 2017, vested in part on June 26, 2018, upon certification by the Compensation Committee that a defined performance objective as to 30% of the target number of share units had been achieved, the acceptance for filing by the U.S. Food and Drug Administration of a New Drug Application for bremelanotide for hypoactive sexual desire disorder in premenopausal women during the defined performance period. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc.
- F2Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest as to 50% June 26, 2019 and as to the remaining shares on June 26, 2020. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc.
- F3Options vest at the rate of 25% per year, starting on June 26, 2019.
- F4Vesting of performance condition stock option grant, made December 12, 2017, which vested in part on June 26, 2018, upon certification by the Compensation Committee that a defined performance objective as to 30% of the target number of share units had been achieved, the acceptance for filing by the U.S. Food and Drug Administration of a New Drug Application for bremelanotide for hypoactive sexual desire disorder in premenopausal women during the defined performance period.